A Multicenter, Open-Label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA Smallpox Vaccine (IMVAMUNE) in 18–40 Year Old Subjects with Diagnosed Atopic Dermatitis-Reference-Cited by-同舟云学术

A Multicenter, Open-Label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA Smallpox Vaccine (IMVAMUNE) in 18–40 Year Old Subjects with Diagnosed Atopic Dermatitis

Published:2015-10-06 Issue:10 Volume:10 Page:e0138348
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Greenberg Richard N,Hurley Yadira,Dinh Dinh V.,Mraz Serena,Vera Javier Gomez,von Bredow Dorothea,von Krempelhuber Alfred,Roesch Siegfried,Virgin Garth,Arndtz-Wiedemann Nathaly,Meyer Thomas Peter,Schmidt Darja,Nichols Richard,Young Philip,Chaplin Paul

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference38 articles.

1. Smallpox: Clinical and epidemiologic features;DA Henderson;Emerg Infect Dis,1999

2. Smallpox vaccines for biodefense: need and feasibility;AW Artenstein;Expert Rev Vaccines,2008

3. Smallpox vaccination reactions, prophylaxis, and therapy of complications;JA Goldstein;Pediatrics,1975

4. . Complications of smallpox vaccination, 1968;JM Lane;N Engl J Med,1969

5. Complications of smallpox vaccination, 1968: Results of ten statewide surveys;JM Lane;J Infect Dis,1970

Cited by 51 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of the Efficacy of Different Schemes for Using Recombinant Vector Vaccines against Ebola Fever, Based on Vaccinia Virus, MVA Strain;Problems of Particularly Dangerous Infections;2024-01-07

2. Prospective monitoring of adverse events following vaccination with Modified vaccinia Ankara - Bavarian Nordic (MVA-BN) administered to a Canadian population at risk of Mpox: A Canadian Immunization Research Network study;Vaccine;2024-01

3. Predicting vaccine effectiveness in Mpox;2023-11-24

4. A Review of the Past, Present, and Future of the Monkeypox Virus: Challenges, Opportunities, and Lessons from COVID-19 for Global Health Security;Microorganisms;2023-11-06

5. High throughput analysis of B cell dynamics and neutralizing antibody development during immunization with a novel clade C HIV-1 envelope;PLOS Pathogens;2023-10-25